| Code | CSB-RA004846MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to CAP-100, targeting CCR7 (C-C chemokine receptor type 7), a G protein-coupled receptor critical for lymphocyte trafficking and immune system organization. CCR7 directs the migration of T cells, B cells, and dendritic cells to lymph nodes and other secondary lymphoid organs by responding to chemokines CCL19 and CCL21. This receptor plays essential roles in adaptive immunity, central tolerance, and immune surveillance. Aberrant CCR7 expression has been implicated in various pathological conditions, including autoimmune diseases, inflammatory disorders, and cancer metastasis, where it facilitates tumor cell migration to lymph nodes and distant organs.
CAP-100 is an established research antibody widely used for investigating CCR7 expression patterns and functional mechanisms in immune cell biology and cancer research. This biosimilar provides researchers with a reliable tool for studying lymphocyte homing, immune cell activation, tumor microenvironment interactions, and metastatic processes. The antibody supports investigations into therapeutic targeting strategies for immune-related diseases and malignancies where CCR7-mediated cell migration is dysregulated.
There are currently no reviews for this product.